# BEXMAB (NCT05428969)

> A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05428969
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Faron Pharmaceuticals Ltd
- Conditions: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Relapsed/Refractory AML
- Interventions: Bexmarilimab; Azacitidine; Venetoclax
- Enrollment: 181
- Primary outcome: Reporting of incidence and frequency of dose limiting toxicities (DLTs).
- Primary outcome: Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and serious adverse events (SAE).
- Primary outcome: Complete response (CR) rate for MDS and CMML-2.
- Primary outcome: Overall response rate (ORR) for MDS and CMML failure to prior HMA.
- Primary outcome: Complete remission with incomplete blood recovery (CRi) for r/r AML.
- Primary outcome: Minimal residual disease (MRD) status for newly diagnosed AML.

## Commentary we found

- X threads: 6
- YouTube: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bexmab-nct05428969

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05428969", "email": "<work email>"}; the inbox owner confirms by the emailed link.